Brought to you by:
SWEDEPAD unplanned interim analysis shows no difference in all-cause mortality for paclitaxel devices
An unplanned interim analysis of the registry-based SWEDEPAD clinical trial, in which patients with peripheral arterial disease (PAD) received treatment with paclitaxel-coated (drug-coated balloons or drug-eluting stents) or uncoated endovascular devices, “did not show a difference between the groups in…
CMS creates new codes for IVL performed below the knee
Shockwave Medical has announced that as part of the calendar year 2021 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule, the Centers for Medicare & Medicaid Services (CMS) has created four new codes for intravascular lithotripsy (IVL) procedures performed…
SVS launches inaugural member census
The Society for Vascular Surgery (SVS) has launched an Annual Physician Member Census aimed at capturing current issues of importance and the changing demographics of the membership body. The inaugural survey, due by Dec. 14, comes as the SVS places…
RelayPlus thoracic stent graft post-approval study reports low operative mortality
Terumo Aortic has announced the midterm results from the RelayPlus thoracic stent graft system post-approval study, revealing low operative mortality and morbidity— supporting its use as a “safe and effective” thoracic aortic aneurysm treatment. Over a three-year period, the RelayPlus…
COVID-related hypercoagulability linked to elevated malfunction rate in temporary hemodialysis catheters
Hypercoagulability in COVID-19 patients leads to an increase in the malfunction rate of temporary hemodialysis catheters—but heparin locking of the catheters is linked to decreased malfunction rates. Those are among the main findings of a study recently published in the…
Fund hope with the SVS Foundation
A gift to the SVS Foundation funds not just things—patient education fliers, research awards and community awareness projects—but also hope for a better future. Hope that screenings identify people at risk for a ruptured abdominal aortic aneurysm. That research uncovers…
Vesper Medical announces first enrollment in the VIVID trial
Vesper Medical recently announced initiation of its Food and Drug Administration (FDA) investigational device exemption (IDE) study, VIVID (Venous stent for the iliofemoral vein investigational clinical trial using the Vesper Duo venous stent system). The VIVID trial is a prospective, multicenter, single-arm study to…
The power of groups: Invest in the SVS PAC
Humans are social animals, and, over time, they have found that their best times are spent in groups. We have just celebrated Thanksgiving, spending time with our most important group, our family, reflecting on our present life situation and giving…
VAM 2021 taking shape, schedule changes to expand programming
Though many individual components will remain the same, the 2021 Vascular Annual Meeting (VAM) will have a different look and feel. “The meeting has been reorganized. We’re creating an expanded version of VAM that will take place Wednesday morning through…
Present imperfect
On the morning of Nov. 9, I received a phone call from my sister. My father had been found unresponsive in his Manhattan apartment and was being taken to the hospital. Ok, I told her, call me when you know…